Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > from Bio Runup
View:
Post by gmcsle on Jun 24, 2010 9:45pm

from Bio Runup

I have received email correspondence from the Chief Operating Officer of Isotechnika, Launa Aspeslet. In summary Dr. Aspelet stated that the August 3rd, 2010 FDA PDUFA date is still valid. The “action letter” that was mentioned in yesterday’s press release was referring to the standard FDA decision process of issuing ”Approval” or a CRL. It was not referring to any specific requests from the FDA. Isotechnika states that they have not been provided with any additional details regarding the “outstanding issues” mentioned by the FDA in the meeting cancellation PR.

My opinion: The cancellation of the FDA Panel was an event that I can not remembering happening in the past. The FDA usually requests an additional 90 days to review anything, take for example QCOR‘s NDA. Because of this I will not be taking another position in ISA.TO (IPHAF). I feel that the official CRL (Complete Response Letter, or FDA rejection) may come at any time, which may send Isotechnika down to pre-FDA Review prices in the $.10 – $.19 range. As always, this is just my opinion and you need to decide for yourself how to invest. If no early CRL is issued, ISA.TO may climb back to $.40. At this point, it is too risky for me.

Me Too!

Comment by NorthStarr on Jun 24, 2010 10:53pm
How about sharing your correspondence  from Launa instead of giving us your twist on what she said??? Seems odd to me the COO of the company took the time to respond to you during this time.Cheers
Comment by macbethorfaust on Jun 24, 2010 11:14pm
Northstar gmclse was only pasting in a comment on biorunup’s site.Biorunup’s perspective is a valid one but remember he is in these plays only for the run up i.e. in situations where the run up is pretty much a given (a pretty good play actually when you think about it)).  When things get uncertain he bails.   And the fact that he didn’t know what was meant by an “action letter ...more  
Comment by WASKERWISK on Jun 24, 2010 11:26pm
Well here’s the thing though about the market.  Is 27 cents the price for a delayed PDUFA i.e. is the perceived delay already priced in?  I mean I for one am already assuming that there will be a delay.  Or will the drop be significant if it is delayed?   Curious to see. Obviously if we are back on things will bounce back rather tremendously and probably well above where ...more  
Comment by NorthStarr on Jun 24, 2010 11:36pm
First of all my apologies to GMCLSEMacbethorfaust, thank you very much for the clarification. I do agree the perspective is a valid one. What got me was they were claiming to have had correspondence from the COO. Thanks for your post, very well said and I couldn't agree more with your take on things.Here is to hopefully good things to come.Cheers
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities